Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 1/20 | 1.00 |
| ▸ | PDGFRA | P16234 | 1/20 | 1.00 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.68 |
| ▸ | EGFR | P00533 | 1/20 | 0.68 |
| ▸ | KDR | P35968 | 2/20 | 0.62 |
| ▸ | AURKA | O14965 | 1/20 | 0.61 |
| ▸ | ABL1 | P00519 | 1/20 | 0.61 |
| ▸ | LCK | P06239 | 1/20 | 0.61 |
| ▸ | LYN | P07948 | 1/20 | 0.61 |
| ▸ | MET | P08581 | 1/20 | 0.61 |
| ▸ | TEK | Q02763 | 1/20 | 0.61 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29573413 | 1.00 | PDGFRB (1.00) | PDGFRBPDGFRAFGFR2EGFRKDR | |
| SCHEMBL7486400 | 0.89 | FGFR2 (0.84) | PDGFRBPDGFRAFGFR2EGFRKDR | |
| SCHEMBL168048 | 0.88 | PDGFRB (0.79) | PDGFRBPDGFRAFGFR2EGFRKDR | |
| SCHEMBL7482292 | 0.88 | PDGFRA (0.78) | PDGFRBPDGFRAFGFR2EGFRKDR | |
| SCHEMBL3894947 | 0.87 | PDGFRA (0.76) | PDGFRBPDGFRAFGFR2EGFRKDR | |
| SCHEMBL4365396 | 0.87 | PDGFRB (0.76) | PDGFRBPDGFRAFGFR2EGFRKDR | |
| SCHEMBL12444104 | 0.86 | PDGFRA (0.76) | PDGFRBPDGFRAFGFR2EGFRKDR | |
| SCHEMBL31060411 | 0.86 | PDGFRA (0.75) | PDGFRBPDGFRAFGFR2EGFRKDR | |
| SCHEMBL14967325 | 0.86 | PDGFRA (0.74) | PDGFRBPDGFRAFGFR2KDRAURKA | |
| SCHEMBL3894972 | 0.85 | PDGFRB (0.74) | PDGFRBPDGFRAFGFR2EGFRKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0860433-A1 | QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES INHIBITING AUTOPHOSPHORYLATION OF GROWTH FACTOR RECEPTOR ORIGINATING IN PLATELET AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | KIRIN BEER KABUSHIKI KAISHA (JP) | 1998-08-26 | — | — | EP | claimed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| US-7875616-B2 | using 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide or imatinib; type I and type II diabetes | HAEGERKVIST ROBERT PER | 2011-01-25 | — | — | US | disclosed |
| US-20080234285-A1 | Combination of Organic Compounds | FELDMAN DAVID LOUIS | 2008-09-25 | — | — | US | disclosed |
| US-20080070922-A1 | Combination of Organic Compounds | BURKEY BRYAN | 2008-03-20 | — | — | US | disclosed |
| EP-1802308-A1 | COMBINATION OF ORGANIC COMPOUNDS | Novartis AG (CH) | 2007-07-04 | — | — | EP | disclosed |
| US-20070072932-A1 | Use of tyrosine kinase inhibitor to treat diabetes | HAEGERKVIST ROBERT P | 2007-03-29 | — | — | US | disclosed |
| WO-2006124544-A2 | USE OF TYROSINE KINASE INHIBITORS IN THE TREATMENT OF METABOLIC DISORDERS | NOVARTIS AG (CH) | 2006-11-23 | — | — | WO | disclosed |
| EP-1708691-A1 | COMBINATION OF ORGANIC COMPOUNDS | Novartis AG (CH) | 2006-10-11 | — | — | EP | disclosed |
| WO-2006041976-A1 | COMBINATION OF ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2006-04-20 | — | — | WO | disclosed |
| WO-2005070432-A1 | USE OF PDGF-R TK INHIBITORS FOR THE TREATMENT OF MYOCARDITIS AND ITS COMPLICATIONS | NOVARTIS AG (CH) | 2005-08-04 | — | — | WO | disclosed |
| WO-2005070406-A1 | COMBINATION OF ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2005-08-04 | — | — | WO | disclosed |
| EP-0860433-B1 | QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES INHIBITING AUTOPHOSPHORYLATION OF GROWTH FACTOR RECEPTOR ORIGINATING IN PLATELET AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | KIRIN BREWERY (JP) | 2002-07-03 | — | — | EP | disclosed |
| US-6143764-A | ETHER DERIVATIVES OF QUINOLINE, ANTITUMOR AGENTS | KIRIN BEER KABUSHIKI KAISHA (JP) | 2000-11-07 | — | — | US | disclosed |
| EP-0860433-A1 | QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES INHIBITING AUTOPHOSPHORYLATION OF GROWTH FACTOR RECEPTOR ORIGINATING IN PLATELET AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | KIRIN BEER KABUSHIKI KAISHA (JP) | 1998-08-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070922-A1 | Combination of Organic Compounds | GIPR, IRS1, IGF1R | PDGFRB 5/4885PDGFRA 11/4885FGFR2 398/4885 |
| US-20080234285-A1 | Combination of Organic Compounds | REN, PDGFRB, PDGFRA | PDGFRB 2/4885PDGFRA 3/4885FGFR2 12/4885 |
| US-20070072932-A1 | Use of tyrosine kinase inhibitor to treat diabetes | ABL2, PDGFRA, ABL1 | PDGFRB 4/4885PDGFRA 2/4885FGFR2 171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.